Tenaya Therapeutics (TNYA) EBITDA (2020 - 2026)

Tenaya Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• In Q1 2026, EBITDA rose 28.36% year-over-year to -$19.3 million; the TTM figure through Mar 2026 stood at -$83.0 million (up 21.45% YoY), while the FY2025 annual figure was -$90.6 million, up 18.35% from the prior year.
• EBITDA was -$19.3 million for Q1 2026 at Tenaya Therapeutics, up from -$20.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$19.3 million in Q1 2026 to a low of -$33.5 million in Q2 2023.
• Historically, EBITDA has averaged -$27.6 million across 5 years, with a median of -$29.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA plunged 140.85% in 2022, then rose 28.36% in 2026.
• A 5-year view of EBITDA shows it stood at -$33.1 million in 2022, then gained by 10.1% to -$29.8 million in 2023, then gained by 19.8% to -$23.9 million in 2024, then climbed by 15.53% to -$20.2 million in 2025, then grew by 4.48% to -$19.3 million in 2026.
• The last three EBITDA figures came in at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.